These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 38953434)
1. Reconstruction of the historic time course of blood-borne virus contamination of clotting factor concentrates, 1974-1992. McClure CP; Kean K; Reid K; Mayne R; Fu MX; Rajendra P; Gates S; Breuer J; Harvala H; Golubchik T; Tarr AW; Irving WL; Makris M; Simmonds P J Med Virol; 2024 Jul; 96(7):e29774. PubMed ID: 38953434 [TBL] [Abstract][Full Text] [Related]
2. Human parvovirus PARV4 in clotting factor VIII concentrates. Fryer JF; Hubbard AR; Baylis SA Vox Sang; 2007 Nov; 93(4):341-7. PubMed ID: 18070279 [TBL] [Abstract][Full Text] [Related]
3. Prevalence of nucleic acid sequences specific for human parvoviruses, hepatitis A and hepatitis E viruses in coagulation factor concentrates. Modrow S; Wenzel JJ; Schimanski S; Schwarzbeck J; Rothe U; Oldenburg J; Jilg W; Eis-Hübinger AM Vox Sang; 2011 May; 100(4):351-8. PubMed ID: 21133933 [TBL] [Abstract][Full Text] [Related]
4. Seroprevalence of parvovirus B19, cytomegalovirus, hepatitis A virus and hepatitis E virus antibodies in haemophiliacs treated exclusively with clotting-factor concentrates considered safe against human immunodeficiency and hepatitis C viruses. Flores G; Juárez JC; Montoro JB; Tusell JM; Altisent C; Juste C; Jardí R Haemophilia; 1995 Apr; 1(2):115-7. PubMed ID: 27214319 [TBL] [Abstract][Full Text] [Related]
5. Virologic and clinical features of primary infection with human parvovirus 4 in subjects with hemophilia: frequent transmission by virally inactivated clotting factor concentrates. Sharp CP; Lail A; Donfield S; Gomperts ED; Simmonds P Transfusion; 2012 Jul; 52(7):1482-9. PubMed ID: 22043925 [TBL] [Abstract][Full Text] [Related]
6. Impact of Blood Transfusion on the Prevalence of HHpgV-1, HPgV-1, and B19V Among Iranian HCV-infected Patients With Hemophilia. Agi E; Hojjatipour S; Namvar A; Bolhassani A J Pediatr Hematol Oncol; 2020 May; 42(4):e213-e218. PubMed ID: 31972722 [TBL] [Abstract][Full Text] [Related]
7. Hepatitis G virus in clotting factor concentrates. Alonso-Rubiano E; Gerber M; Friedman P; Hodges S; Leissinger C Haemophilia; 2003 Jan; 9(1):110-5. PubMed ID: 12558787 [TBL] [Abstract][Full Text] [Related]
8. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization. Santagostino E; Mannucci PM; Gringeri A; Azzi A; Morfini M; Musso R; Santoro R; Schiavoni M Transfusion; 1997 May; 37(5):517-22. PubMed ID: 9149778 [TBL] [Abstract][Full Text] [Related]
9. Frequency of contamination of coagulation factor concentrates with novel human parvovirus PARV4. Schneider B; Fryer JF; Oldenburg J; Brackmann HH; Baylis SA; Eis-Hübinger AM Haemophilia; 2008 Sep; 14(5):978-86. PubMed ID: 18565125 [TBL] [Abstract][Full Text] [Related]
10. Prevalence of hepatitis C antibodies in patients with clotting disorders in Victoria. Relationship with other blood borne viruses and liver disease. Leslie DE; Rann S; Nicholson S; Fairley CK; Gust ID Med J Aust; 1992 Jun; 156(11):789-92. PubMed ID: 1321326 [TBL] [Abstract][Full Text] [Related]
19. High frequencies of exposure to the novel human parvovirus PARV4 in hemophiliacs and injection drug users, as detected by a serological assay for PARV4 antibodies. Sharp CP; Lail A; Donfield S; Simmons R; Leen C; Klenerman P; Delwart E; Gomperts ED; Simmonds P J Infect Dis; 2009 Oct; 200(7):1119-25. PubMed ID: 19691429 [TBL] [Abstract][Full Text] [Related]
20. Has hepatitis A virus been transmitted by clotting factor concentrates among hemophiliacs in the United States? Mosley JW Vox Sang; 1994; 67 Suppl 4():12-5; discussion 24-6. PubMed ID: 7831863 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]